Mesenchymal stem cells

apceth Biopharma’s proprietary technology is based on a kind of adult stem cells called mesenchymal stem cells (MSC) and their genetic modification.

MSC can be isolated with simple methods from a variety of human tissues, such as bone marrow, adipose tissue, placenta, umbilical cord or umbilical cord blood. Bone marrow is the usual tissue source of MSC for the production of apceth Biopharma’s cell therapeutics. As multipotent progenitor cells, MSC can differentiate into a variety of cell lineages, including osteocytes (bone), chondrocytes (cartilage), adipocytes (fat) or muscles cells.

In cell culture MSC can be expanded to the clinical scale in a short period of time to produce one or more therapeutically active cell doses. In the process MSC retain their stem cell characteristics, such as the ability to self-renew and differentiate.



The therapeutic potential of MSC is well proven in a number of preclinical and clinical studies over the last decade. In particular, these cells have the capacity to:

  • promote tissue regeneration of diseased and damaged tissues;
  • act anti-inflammatory, which means they modulate the body’s immune response in such a way as to reduce and prevent inflammation;
  • actively migrate or “home” towards damaged tissues and sites of inflammation and tumor growth in the body.

The mechanisms behind the therapeutically promising effects of MSC and MSC homing are complex. Paracrine interactions based on the secretion and interplay of soluble factors (chemokines) between diseased tissue and tumors on the one side, and MSC on the other side play a major role here.

The unique MSC features enable therapeutic application of these cells in almost all established disease areas: cancer, immunomodulation, organ transplantation and post-transplant reactions, autoimmunity, regenerative medicine, cardiovascular diseases, neurodegenerative disorders, etc. Thousands of clinical studies in the past 15 years confirm the excellent safety profile of MSC therapeutics.